Advanced gastric cancer with peritoneal oligometastases treated with adaptive radiotherapy and concurrent chemotherapy
Language English Country Czech Republic Media print
Document type Journal Article, Case Reports
PubMed
39174332
DOI
10.48095/ccko2024286
PII: 138289
Knihovny.cz E-resources
- Keywords
- Drug therapy, image-guided radiotherapy, intensity-modulated radiotherapy, stomach neoplasms,
- MeSH
- Chemoradiotherapy * MeSH
- Drug Combinations MeSH
- Tegafur * therapeutic use administration & dosage MeSH
- Oxonic Acid * therapeutic use administration & dosage MeSH
- Humans MeSH
- Stomach Neoplasms * pathology therapy drug therapy MeSH
- Peritoneal Neoplasms * secondary therapy MeSH
- Antimetabolites, Antineoplastic therapeutic use MeSH
- Aged MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Names of Substances
- Drug Combinations MeSH
- Tegafur * MeSH
- Oxonic Acid * MeSH
- Antimetabolites, Antineoplastic MeSH
- S 1 (combination) MeSH Browser
BACKGROUND: There are no reports of concurrent chemoradiotherapy for gastric cancer with peritoneal oligometastases. CASE DESCRIPTION: A 70-year-old man with gastric cancer and peritoneal oligometastases received concurrent adaptive radiotherapy and oral S-1. After radiotherapy, S-1 was discontinued, and 2 years later the tumor had completely regressed, with no recurrence or metastasis 6 years after radiotherapy. CONCLUSION: Peritoneal oligometastatic gastric cancer may be a candidate for curative treatment with concurrent adaptive radiotherapy and oral S-1.
References provided by Crossref.org
